Macaluso FS, Fries W, Viola A, Cappello M, et al. Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study J Crohns Colitis 2025 Oct 13:jjaf175. doi: 10.1093.
PMID: 41081746